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SUMMARY
The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through 
amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit MYC 
function as potential cancer therapy. Using a novel covalent inhibitor of cyclin-dependent kinase 7 
(CDK7) to disrupt the transcription of amplified MYCN in neuroblastoma cells, we demonstrate 
downregulation of the oncoprotein with consequent massive suppression of MYCN-driven global 
transcriptional amplification. This response translated to significant tumor regression in a mouse 
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model of high-risk neuroblastoma, without the introduction of systemic toxicity. The striking 
treatment selectivity of MYCN-overexpressing cells correlated with preferential downregulation of 
super-enhancer-associated genes, including MYCN and other known oncogenic drivers in 
neuroblastoma. These results indicate that CDK7 inhibition, by selectively targeting the 
mechanisms that promote global transcriptional amplification in tumor cells, may be useful 
therapy for cancers that are driven by MYC family oncoproteins.
INTRODUCTION
Many human cancers depend on the deregulated expression of MYC family members for 
their aberrant growth and proliferation, with elevated expression of these oncogenes 
predicting aggressive disease and a poor clinical outcome (Eilers and Eisenman, 2008; 
Wasylishen and Penn, 2010). Deactivation of MYC in cell lines and MYC-induced 
transgenic tumors causes proliferative arrest and tumor regression (Arvanitis and Felsher, 
2006; Soucek et al., 2008), suggesting that effective targeting of MYC proteins would have 
broad therapeutic benefit. Recently, several groups reported that oncogenic MYC elicits its 
plethora of downstream effects in tumor cells through global transcriptional amplification, 
leading to massively upregulated expression of genes involved in multiple processes (Lin et 
al., 2012; Loven et al., 2012; Nie et al., 2012; Schuhmacher and Eick, 2013). When present 
at physiological levels, MYC binds to the core promoters of actively transcribed genes; 
however, in tumor cells with MYC overexpression, increased MYC levels are observed at 
both the core promoters and enhancers of the same set of genes, resulting in increased levels 
of transcripts per cell. This mechanism provides an explanation for the lack of a common 
MYC transcriptional signature and for the diverse effects of deregulated MYC in cancer 
cells. Another general feature of deregulated MYC is its transcriptional regulation by super-
enhancers (SEs), clusters of enhancers that are densely occupied by transcription factors, 
cofactors and chromatin regulators (Hnisz et al., 2013). Super-enhancers (SEs) are acquired 
by cancer cells through gene amplification, translocation or transcription factor 
overexpression. They facilitate high-level expression of genes including MYC, whose 
protein products are critical for the control of cell identity, growth and proliferation, and 
which are especially sensitive to perturbation (Chapuy et al., 2013; Hnisz et al., 2013; Loven 
et al., 2013). These emerging insights into the role of oncogenic MYC as a SE-associated 
transcriptional amplifier suggest that strategies aimed at disrupting the associated molecular 
mechanisms might provide useful therapy for different MYC-dependent tumors.
The transcription cycle of RNA polymerase II (Pol II) is regulated by a set of cyclin-
dependent kinases (CDKs) that have critical roles in transcription initiation and elongation 
(Larochelle et al., 2012). In contrast to the cell cycle CDKs which are largely responsible for 
cell cycle transition, these transcriptional CDKs (especially CDK7, a subunit of TFIIH, and 
CDK9, a subunit of pTEFb) phosphorylate the carboxy-terminal domain (CTD) of Pol II, 
facilitating efficient transcriptional initiation, pause release and elongation. Moreover, most 
CDKs are activated through T-loop phosphorylation by a CDK-activating kinase (CAK), 
which in metazoans appears to be uniquely controlled by CDK7 (Fisher and Morgan, 1994; 
Glover-Cutter et al., 2009; Larochelle et al., 2012; Larochelle et al., 2007; Rossignol et al., 
1997; Serizawa et al., 1995). Inhibition of transcriptional CDKs primarily affects the 
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accumulation of transcripts with short half-lives, including antiapoptosis family members 
and cell cycle regulators (Garriga and Grana, 2004; Lam et al., 2001), rendering this group 
of kinases ideal candidates for blocking MYC-dependent transcriptional amplification.
Here we investigate whether inhibition of transcriptional CDKs can be exploited to disrupt 
aberrant MYC-driven transcription, using the deregulated expression of MYCN as a model. 
The MYCN protein shares most of the physical properties of MYC (Kohl et al., 1986) and is 
considered functionally interchangeable, based on the similarity of their transcriptional 
programs, the cellular phenotypes they induce, and the ability of MYCN to replace MYC 
during murine development (Boon et al., 2001; Malynn et al., 2000; Toyoshima et al., 2012). 
In neuroblastoma (NB), a pediatric solid tumor arising in the peripheral sympathetic nervous 
system, MYCN amplification is typically associated with a dismal prognosis, regardless of 
the treatment used (Brodeur et al., 1984; Seeger et al., 1985).
We demonstrate that THZ1, a newly developed covalent inhibitor of CDK7 (Kwiatkowski et 
al., 2014), selectively targets MYCN-amplified NB cells, leading to global repression of 
MYCN-dependent transcriptional amplification. This response induces sustained growth 
inhibition of tumors in a mouse model of NB. The remarkable sensitivity of MYCN-
amplified cells to CDK7 inhibition is associated with preferentially reduced expression of 
SE-associated oncogenic drivers, especially MYCN.
RESULTS
THZ1 Exerts Potent and Selective Effects in MYC-deregulated Cells
To identify CDKs whose depletion might lead to decreased MYCN expression and 
subsequent apoptosis, we performed a short-hairpin (shRNA) knockdown screen of CDKs 
with known transcriptional activities (CDKs 7–9, 12, 13, 19) in Kelly cells, a human NB line 
that expresses very high levels of MYCN RNA and protein due to genomically amplified 
MYCN (100–120 copies per cell) (Schwab et al., 1983). Genetic depletion of CDK7, 8, 9 or 
19 led to marked decreases of MYCN RNA and protein with a concomitant increase in 
cleaved caspase 3 (CC3) expression (Figures S1A and S1B). To reproduce these results 
pharmacologically, we tested a panel of 11 inhibitors with activity against transcriptional 
CDKs in three MYCN-amplified cell lines, observing a range of sensitivities, with the 
highest potency (IC50, 6–9 nM) shown by a newly developed covalent 
phenylaminopyrimidine inhibitor of CDK7, THZ1 (Kwiatkowski et al., 2014) (Figure S1C 
and Table S1). Similar results were obtained when THZ1 was tested against a larger panel of 
MYCN-amplified NB cell lines with varying levels of MYCN expression (Figures 1A and 
S1D). Importantly, NB cells without MYCN amplification were far less sensitive to THZ1, 
with IC50 values averaging 10 times higher than those of MYCN-amplified cells (Figure 1A 
and Table S1). Notably, the NBL-S cell line, which expresses high levels of MYCN without 
genomic amplification (Cohn et al., 1990) (Figure S1D), was quite sensitive to THZ1, while 
two nontransformed lines (B6-MEFs and NIH-3T3) were relatively insensitive (Figure 1A). 
MYCN-amplified cells also showed enhanced sensitivity to THZ1R, a reversible analog of 
THZ1 that lacks the acrylamide moiety required for covalent bond formation, although it 
was not as potent as the covalent inhibitor (Figure 1B). The strong selectivity of THZ1 for 
MYCN-amplified cells was not restricted to NB, but extended to H262-BT111, a human 
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primitive neuroectodermal tumor cell line expressing amplified MYCN (K. Ligon, personal 
communication) and Raji and Daudi lymphoma cells, both characterized by MYC 
overexpression due to chromosomal translocation (Nishikura et al., 1985; Veronese et al., 
1995) (Figure S1E). To probe this preferential effect further, we tested the extent of target 
engagement in NB cells, using a biotinylated derivative of THZ1 (bio-THZ1) with or 
without THZ1 pre-treatment. Bio-THZ1 consistently bound to CDK7 in both MYCN-
amplified and nonamplified untreated cells (Figure S1F), but became less efficient after 
THZ1 treatment, suggesting that target recognition was not a major factor in the enhanced 
inhibitory effects of THZ1 in MYCN-amplified cells.
Next, we studied the growth inhibitory effects of THZ1. MYCN-amplified cells treated with 
THZ1 underwent cell cycle arrest in G2/M at 24 hours, an effect that was not observed in 
MYCN-nonamplified NB cells, even after 48 hours (Figure 1C). Moreover, THZ1 led to a 
profound induction of apoptosis in high MYCN-expressing cells, but not in cells expressing 
nonamplified MYCN (Figures 1D and S1G). Together, these data indicate that THZ1 induces 
selective cytotoxicity not only in NB cells with MYCN amplification, but also in other 
cancers overexpressing either the MYCN or MYC oncogene.
THZ1 Inhibits Tumor Growth in a Mouse Model of Human MYCN-amplified NB
Given the relative lack of target specificity of past CDK inhibitors, leading to adverse effects 
in normal cells (Lapenna and Giordano, 2009), we assessed the tolerability of THZ1 in non-
tumor-bearing mice (n = 6) treated with 10 mg/kg intravenously twice daily. No systemic 
toxicity was observed even after 4 weeks of continuous administration (data not shown). We 
next tested the therapeutic effects of THZ1 in xenograft models of MYCN-amplified human 
NB derived from subcutaneous flank injection of Kelly cells. When tumors reached an 
optimal size (mean volume, ~150 mm3; range, 75–235 mm3), the animals were divided into 
two groups and treated with vehicle (n=9) or THZ1 as above; (n=14). Treatment was 
continued for a mean of 20 days (range, 15–24 days) in the control group and 24 days 
(range, 20–28 days) in the THZ1 group. Mice receiving THZ1 had a statistically significant 
reduction in tumor growth, again without toxicity (Figure 1E). Two animals remained free 
of tumor recurrence at 35 and 128 days post-treatment.
Tumors from vehicle-treated mice displayed histological features of human NB with poorly 
differentiated, small round blue cells displaying high mitotic activity (Figure 1F). By 
contrast, the vast majority of tumor cells in the THZ1-treated animals demonstrated 
necrosis, reduced proliferative activity and increased apoptosis. To ensure target 
engagement in the tumor cells, we used bio-THZ1 to pull down CDK7 in cell lysates from 
both vehicle- and THZ1-treated animals, noting decreased binding with bio-THZ1 in the 
latter (Figure S1H). We also confirmed that the lack of toxicity in the animal models did not 
reflect THZ1 selectivity for human CDK7, as bio-THZ1 formed a complex with murine 
CDK7 in cell lysates from NIH-3T3 cells treated with THZ1 (Figure S1H). These results 
demonstrate the feasibility of specifically targeting CDK7 in tumor cells driven by 
deregulated MYC or MYCN.
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THZ1 Affects Both Transcription and Cell Cycle Progression in MYCN-amplified Cells
As a transcriptional kinase, CDK7 exerts its effects through regulation of RNA Pol II-
mediated transcriptional initiation and pause release, while also activating other CDKs 
through its CAK activity (Glover-Cutter et al., 2009; Larochelle et al., 2012; Palancade and 
Bensaude, 2003). We observed a dose-dependent decrease in the initiation-associated serine 
5 (S5) and serine 7 (S7), and the elongation-associated serine 2 (S2) Pol II phosphorylation 
in MYCN-amplified but not nonamplified cells treated with THZ1 (Figures 2A and S2A). 
Pol II CTD phosphorylation was also downregulated in tumor cells from animals treated 
with THZ1 (Figure 2B). Downregulation of CDK7 phosphorylation was seen in MYCN-
amplified cells (Figure S2B), consistent with the finding that CDK7 is regulated by 
phosphorylation within its own activation (T) loop (Larochelle et al., 2012). Phosphorylation 
of CDK9 was also decreased in MYCN-amplified cells (Figure S2C), reinforcing the effect 
of THZ1 on transcription elongation. Total protein levels of CDK9 were also decreased in 
these cells but not nonamplified cells, suggesting that THZ1-induced CDK7 inhibition might 
also target the transcription of CDK9 (Figure S2C).
The decrease in Pol II phosphorylation after THZ1 treatment in MYCN-amplified cells 
coincided with the loss of the short-lived anti-apoptotic protein MCL1 (Figure 2C). Similar 
effects on Pol II CTD phosphorylation and MCL1 levels were observed in Raji, Daudi and 
H262-BTIII cells, all of which depend on MYC or MYCN overexpression and are sensitive to 
THZ1 (Figure S2D). Importantly, the effects of THZ1, including Pol II CTD 
phosphorylation and the induction of apoptosis, could be rescued by a mutation in the 
covalent binding site of CDK7 (CDK7C312S) (Figure S2E), indicating on-target effects of 
THZ1 on CDK7.
CDK7 also stimulates cell cycle progression by activating CDKs 1 and 2 through its T-loop 
phosphorylation function (Larochelle et al., 2007). We observed a time-dependent decrease 
in CDK1 and 2 phosphorylation, and in other proteins involved in cell cycle regulation (pRB 
and E2F), that was more striking in MYCN-amplified cells (Figures 2D and S2F). However, 
the Pol II inhibitor triptolide appeared to show selectivity for MYCN-overexpressing cells, 
compared to purvanolol which primarily targets cell cycle CDKs (Figure S2G). Thus, 
although THZ1 causes cytotoxicity through transcriptional as well as cell cycle inhibition in 
MYC-driven tumor cells, the latter effect is most likely through decreased transcription of 
cell cycle CDKs.
CDK7 Inhibition causes Widespread Transcriptional Shutdown in MYCN-amplified NB 
Cells
Because THZ1 preferentially downregulates RNA Pol II CTD phosphorylation in MYCN-
amplified cells (Figures 2A and S2A), we next compared the consequences of CDK7 
inhibition on global gene expression in MYCN-amplified (Kelly and IMR-32) vs. 
nonamplified (SH-SY5Y) cells following exposure to 100 nM THZ1 for 6 hours. Expression 
profiling was performed with “spike-in” RNA standards normalized to cell number to enable 
accurate detection of differences in total RNA levels in cells with or without MYCN 
overexpression (Loven et al., 2012).
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We observed a genome-wide decrease in the mRNA expression levels of most actively 
transcribed genes in MYCN-amplified cell lines compared to DMSO-treated cells (Figure 
3A). This widespread downregulation of gene expression was not apparent in MYCN-
nonamplified SH-SY5Y cells treated with the same dose and duration of THZ1 (Figure 3A). 
Indeed, the percentage of actively transcribed genes significantly downregulated in these 
cells was only 7.5%, contrasting with 63% for Kelly and 68% for IMR-32 MYCN-amplified 
cells (false discovery rate, FDR<0.05) (Figure 3B). Moreover, Kelly and IMR-32 cells had 
55% (n=10,292) downregulated transcripts in common, while only 12% (n=1225) of these 
were also downregulated in SH-SY5Y cells (out of 18,665 genes) (Figure 3C). The most 
downregulated genes and gene sets in the MYCN-amplified cells were transcriptional and 
cell cycle regulators (Figures S3A–B); including transcripts of CDKs and their partner 
cyclins (Figures 3D and S3C). Comparison of expression profiles of MYCN-amplified cells 
exposed to THZ1 with those exposed to the general transcription inhibitor actinomycin D 
revealed a significant correlation between the two (R2 = 0.76) (Figure 3E). These results led 
us to conclude that CDK7 inhibition, through THZ1, preferentially downregulates global 
transcription in MYCN-amplified NB cells, affecting most active genes.
THZ1 Targets Deregulated MYCN in NB Cells
The selectivity of THZ1 for MYC/MYCN-deregulated cells led us to investigate its effects 
on MYCN expression and function. We observed that MYCN mRNA was among the top 
15% of significantly downregulated transcripts in NB cell lines most sensitive to THZ1. 
Moreover, transcripts differentially regulated on exposure to THZ1 revealed enrichment for 
previously published MYCN/MYC target gene sets (Figure S4A). THZ1 treatment resulted 
in a dose- and time-dependent downregulation of MYCN mRNA and protein levels in 
MYCN-amplified cells (Figures 4A and 4B), which were rescued by overexpression of the 
CDK7C312S mutant (Figure S4B), similar to observations with an ATP analogue in 
colorectal carcinoma cells expressing a CDK7 mutation (Glover-Cutter et al., 2009). We 
also observed downregulation of MYCN protein levels in the human NB tumors from mice 
that responded to THZ1 (Figure 4C). These effects primarily reflected a reduction in MYCN 
transcripts, as comparison of MYCN protein turnover in MYCN-amplified cells exposed to 
either THZ1 or actinomycin D showed largely similar rates of degradation (Figure S4C). 
Finally, analysis of MYCN occupancy at the promoters of two of its known transcriptional 
targets, MDM2 (Slack et al, 2005) and MCL1 (Labisso et al., 2012), revealed significantly 
decreased MYCN binding, consistent with the disruption of MYCN function by THZ1 
(Figure 4D).
Next, we determined whether genetic depletion of MYCN mimicked the effects of THZ1 in 
MYCN-amplified cells. Abrogation of amplified MYCN expression in Kelly cells using 
shRNA knockdown led to decreased Pol II CTD phosphorylation at S2, S5 and S7 (Figure 
4E), similar to our findings with THZ1 treatment. The inhibition of transcription associated 
with MYCN knockdown was coupled with complete loss of MCL1 and subsequent cell death 
(Figure 4E). We next asked whether ectopic expression of MYCN would sensitize cells to 
THZ1. MYCN-nonamplified SH-SY5Y cells were engineered to express the oncogene by 
lentiviral transduction, resulting in approximately 380-fold increases in MYCN mRNA and 
protein levels (Figure 4F), equivalent to those in MYCN-amplified cells (Figure S1D). 
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Ectopic expression of MYCN in these cells led to a 5-fold greater sensitivity to THZ1 
compared with untransfected or vector control-transfected SH-SY5Y cells (Figure 4G). 
Together, these results indicate that THZ1 specifically targets deregulated MYCN in NB 
cells, sensitizing them to the inhibitor.
Amplified MYCN Induces Global Transcriptional Amplification That is Inhibited by THZ1
Downregulation of MYCN alone seemed insufficient to account for the widespread effects of 
THZ1 on the transcriptional output of cells harboring amplified MYCN. We therefore 
questioned whether deregulated MYCN, like MYC, binds promiscuously to active genes, 
leading to global transcriptional amplification, and whether THZ1 preferentially disrupts this 
effect. Indeed, ectopic expression of MYCN in SH-SY5Y cells led to increased cell size 
(Figure S5A), and significantly increased expression of all active transcripts (Figures 5A and 
S5B). Moreover, THZ1 treatment led to significant downregulation of transcriptional output 
in these cells (Figure 5B) with induction of apoptosis, although MYCN protein levels were 
not affected (Figure 5C). Furthermore, shRNA knockdown of MYCN in MYCN-amplified 
cells led to a striking downregulation of global gene expression in comparison to their 
control shRNA-expressing counterparts (Figures 5D and 5E), again underscoring the 
widespread transcriptional effects of deregulated MYCN. To determine the extent to which 
these effects mirrored those of CDK7 inhibition, we compared the expression profiles of 
MYCN-amplified cells expressing a MYCN shRNA with those of THZ1-treated cells, noting 
significant downregulation of the actively transcribed genes in both types of cells, with a 
close correlation between the top 500 downregulated transcripts in THZ1-treated cells and 
those in MYCN shRNA-depleted cells (Figures 5F and S5C). Hence, disruption of MYCN-
induced transcriptional amplification also contributes to the striking effects of THZ1.
Super-enhancers Can Account for the Selectivity of THZ1 for MYCN-amplified NB Cells
We observed that the ectopic overexpression of MYCN in nonamplified cells led to global 
transcriptional upregulation and sensitization to the growth inhibitory effects of THZ1, 
although the latter effect did not approach the levels seen in cells with endogenously 
amplified MYCN. We therefore investigated the possible contribution of super-enhancers 
(SEs) to the extreme susceptibility of endogenous MYCN-amplified cells to THZ1. Using 
chromatin immunoprecipitation with high-throughput sequencing (ChIP-seq) of histone 
H3K27 acetylation (H3K27ac), a mark of active enhancers (Hnisz et al., 2013), we first 
identified enhancer regions in MYCN-amplified Kelly and nonamplified SH-SY5Y cells 
(Figure S6A). In both cell types, a subset of H3K27ac-bound enhancers (Kelly 6.2%, SH-
SY5Y, 5.4%) had a significantly higher signal than regular enhancers and were therefore 
classified as SEs (Loven et al., 2013; Whyte et al., 2013) (Figure 6A). We also analyzed the 
occupancy of H3K4 monomethylation, a mark that colocalizes with H3K27ac in strong 
enhancers, noting a high concordance (94–99%) with enhancers identified by H3K27ac 
analysis (Figures 6B and S6B).
The SEs in MYCN-amplified cells were either unique or disproportionately loaded with 
H3K27ac, with the largest SE being associated with the MYCN oncogene itself, having an 
H3K27Ac signal that was at least 10 times greater than that of any other SE in either these 
or MYCN-nonamplified cells (Figures 6A and 6B). Since the MYCN SE in Kelly cells is 
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contained within the MYCN amplicon, we questioned whether its SE status merely reflected 
the increased number of copies of the amplified gene. To investigate this possibility, we 
estimated the signal of a single copy of MYCN, and recalculated its rank within the list of 
enhancers. A single copy of the MYCN enhancer still fell within the group of SEs (ranked 
250 out of 746), indicating that increased gene copy number does not account for the high 
SE signal associated with MYCN. The majority of genes associated with the remaining top-
ranked SEs were master transcription factors critical to sympathetic neuronal development 
and cell identity including PHOX2B (Pattyn et al., 1999; Stanke et al., 1999), GATA2 
(Tsarovina et al., 2004), HAND2 (Howard et al., 2000) and DBH (Mercer et al., 1991) 
(Figures 6A and 6C). Another major oncogenic driver in NB, the receptor tyrosine kinase 
ALK (George et al., 2008), was associated with a unique top-ranked SE in MYCN-amplified 
cells (Figures 6A and 6C). In general, the SE domains associated with MYCN amplification 
correlated with pathways involved in the regulation of transcription, while those in 
nonamplified cells were primarily related to cell adhesion, invasion, metastasis and receptor 
tyrosine kinase pathways (Figures 6D and S6C). To ensure that the SEs in the cultured cells 
mirrored those of human NB, we analyzed H3K27ac occupancy in three primary tumors 
(Figures 6E and S6D). Consistent with our cell line data, the largest SE in MYCN-amplified 
samples NB#1 and NB#2 was associated with MYCN (Figures 6E and S6E). SEs associated 
with PHOX2B and HAND2 were identified in all tumor samples (Figure 6E), in keeping 
with their lineage-specific role in sympathetic neuronal development.
To determine whether the occurrence of SEs correlated with increased Pol II occupancy, we 
used ChIP-seq analysis of Pol II and observed that the proximal promoter regions of SE-
associated genes had higher levels of Pol II occupancy compared with regular enhancers in 
both MYCN-amplified and nonamplified cells, although the difference was much more 
striking in the former (Figure 7A). THZ1 treatment led to a striking reduction in Pol II 
binding at the promoter regions and gene bodies of SE-associated genes in MYCN-amplified 
but not nonamplified cells (Figure 7A). Pol II binding at regular enhancer-associated genes 
was not appreciably affected by THZ1 in either cell type (Figure 7A). The reduction in Pol 
II occupancy with THZ1 was observed at the transcription start and end sites of genes 
associated with the top-ranked SEs, including MYCN, suggesting that their expression was 
severely curtailed in these cells (Figure 7B). Indeed, RNA expression of SE-associated 
genes was significantly reduced after THZ1 treatment in MYCN-amplified cells (Figure 7C) 
but not of the same genes in MYCN-nonamplified cells (Figure 7C). Thus, not only do SEs 
in MYCN-amplified cells cause high-level expression of oncogenic drivers and genes that 
determine cell identity, but they also confer exquisite selectivity to perturbation by THZ1.
DISCUSSION
Here we demonstrate that the genomically amplified MYCN oncogene, by promoting the 
development of SEs, leads to upregulation of the active transcriptional program of NB cells, 
sensitizing them to inhibition of CDK7, a widely expressed regulator of transcription and 
cell cycle transition. This effect suppresses essentially all active transcripts, especially those 
responsible for the uncontrolled proliferation that characterizes the cancer cell state, leading 
to potent and selective cytotoxicity while sparing normal cells. The high potency of the 
CDK7 inhibitor, THZ1 can be explained in part by its unprecedented mode of binding - the 
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formation of a covalent bond with a unique cysteine residue outside the kinase domain - 
resulting in prolonged and irreversible CDK7 inactivation (Kwiatkowski et al., 2014). This 
feature contrasts with other transcriptional CDK inhibitors, including flavopiridol, 
roscovitine and CR-8 (Table S1), all of which rely on ATP-competitive modes of binding 
and whose effects on transcription would therefore be expected to be transient. The 
selectivity of THZ1 for MYCN-amplified cells can be attributed to the perturbation of SEs 
associated with deregulated MYCN and other oncogenic drivers.
Despite risk-based treatment strategies for MYCN-amplified NB, responses tend to be brief, 
with early relapses that are almost uniformly fatal (Matthay et al., 1999). Finding suitable 
ways to inhibit MYCN, or any MYC family member for that matter, has been notoriously 
difficult. A recent approach is the modulation of bromodomain and extraterminal (BET) 
domain coactivator proteins such as BRD4, which associates with acetylated chromatin and 
promotes transcriptional activation (Delmore et al., 2011; Loven et al., 2013; Puissant et al., 
2013). After successful testing of the BRD4 inhibitor JQ1 in MYC-dependent multiple 
myeloma models (Delmore et al., 2011), a positive correlation between MYCN amplification 
and sensitivity to JQ1 was demonstrated in the majority of MYCN-amplified NB models 
tested (Puissant et al., 2013). However, others reported growth inhibition of NB using the 
structurally distinct BRD4 inhibitor I-BET726, irrespective of MYCN amplification status or 
MYC/MYCN expression levels (Wyce et al., 2013). The intervention we describe has a 
number of novel features that would support the clinical development of covalent CDK7 
inhibitors for use against MYCN-amplified NB and other MYC-driven cancers. These 
include the ability to achieve potent growth inhibition with relatively low doses of THZ1, 
the lack of off-target effects and the absence of discernible toxicity in a mouse model of NB.
Multiple studies argue that MYC is a global transcriptional amplifier (Lin et al., 2012; 
Loven et al., 2012; Nie et al., 2012; Schuhmacher and Eick, 2013), although a recent report 
has suggested that a portion of this amplification is indirect (Sabo et al., 2014). We believe 
the transcriptional amplification effects of MYC are direct at the vast majority of active 
genes and that differences in interpretation of direct vs. indirect effects are due to differences 
in interpretation of ChIP-seq data thresholds. We demonstrate here that deregulated MYCN 
functions as a transcriptional amplifier of the cell’s existing gene expression program rather 
than a specific target gene set. This effect was not detectable in earlier data sets on MYCN-
amplified tumor samples because of a limitation of microarray analysis, which in 
conventional approaches assumes similar levels of total RNA in all the samples (Loven et 
al., 2012).
Although in principle, blockade of CDK7 function would be expected to inhibit the 
expression of any gene poised to undergo transcription, our direct demonstration that 
manipulation of MYCN levels can modulate the sensitivity to THZ1 supports the idea that 
MYC-induced transcriptional amplification is crucial to THZ1 activity. This transcriptional 
dependency was illustrated by the massive transcriptional shutdown in MYCN-amplified 
cells with relatively low doses of THZ1 (Figure 3). By contrast, although CDK transcripts 
were downregulated by THZ1 in MYCN-nonamplified cells, this effect did not produce the 
same profound impact seen in MYCN-amplified cells, providing further evidence that 
aberrant MYCN expression and the resultant global amplification of transcription are 
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necessary for cell sensitivity to THZ1. This critical dependency on transcriptional 
amplification would account for the selective killing of MYCN-amplified cells by THZ1 
without inducing toxic side effects in mice. The unique SE landscapes of MYCN-amplified 
cells also dictate their response to THZ1. Indeed, genes involved in the oncogenic state - 
such as MYCN and ALK, and those that specify sympathetic neuronal cell identity including 
PHOX2B and HAND2 - were associated with SEs and were far more susceptible to THZ1 
than either their counterparts in MYCN-nonamplified cells or genes driven by regular 
enhancers. This selectivity of THZ1 for MYCN-amplified cells could stem from its inhibition 
of the increased Pol II activity at SE-associated genes, leading to downregulation of MYCN 
expression as well as that of the entire transcriptional program of the cell.
Our data suggest that the cytotoxicity induced by THZ1 in MYCN-driven NB cells is 
mediated by inhibition of both MYCN expression and MYCN-stimulated global 
transcriptional amplification (Figure 7D). Amplified MYCN invades the core promoters and 
enhancer regions of actively transcribed genes, resulting in the formation of SEs at key 
genes underlying the cancer cell state, including MYCN, and ultimately in transcriptional 
amplification. THZ1, by irreversibly inhibiting CDK7, blocks transcription of MYCN 
(Figure 4) as well as MYCN-induced amplification of global gene transcription. The latter 
conclusion is based on the widespread inhibition of transcription in MYCN-amplified cells 
(Figure 3), the highly significant correlation between the transcripts that were 
downregulated by THZ1 and those resulting from genetic depletion of MYCN and the fact 
that ectopic expression of MYCN in non-MYCN-overexpressing cells sensitizes these cells to 
widespread transcriptional inhibition by THZ1 (Figures 4 and 5). Together, these two 
processes effectively deprive tumor cells of the proliferative signals to which they have 
become addicted, leading to apoptotic death. Nevertheless, this mechanism is not necessarily 
specific to deregulated MYCN or MYC. Rather, we suggest that inhibition of CDK7 or 
perhaps other transcriptional CDKs would be effective in any context in which tumor cells 
rely on high-level expression of one or more oncogenic transcription factors for their 
aberrant growth and survival. However, the net inhibitory effect is likely to be much more 
profound in cancers that depend on MYC (or MYCN) as the oncogenic driver.
In conclusion, we use NB and a newly developed transcriptional CDK inhibitor to 
demonstrate the potency and selectivity of a potential treatment strategy that targets global 
transcriptional amplification in MYC-driven tumors. Our results suggest that the mechanism 
by which oncogenic MYC gains control over myriad cellular processes to induce tumor 
formation also exposes a vulnerability that can be exploited therapeutically. By using THZ1 
to disable essential components of the cancer cells’ transcriptional machinery, we show that 
widespread suppression of transcription in MYC-dependent cancers is not only feasible, but 
also spares normal cells from toxicity.
EXPERIMENTAL PROCEDURES
Cell Lines
Human NB cell lines (from the Children’s Oncology Group) and Raji and Daudi cells 
(provided by D. Sabatini, Massachusetts Institute of Technology) were grown in 
RPMI-1640, 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep; 
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Invitrogen). H262-BT111 primitive neuroectodermal tumor cells (provided by K. Ligon, 
Dana-Farber Cancer Institute, DFCI), were grown in neuronal stem cell (NSC) media with 
heparin, NSC supplement (Stem Cell Technologies), 1% pen/strep, erythrocyte growth 
factor (EMD Millipore) and fibroblast growth factor (Life Technologies). NIH-3T3 cells 
(purchased from ATCC) and B6-MEFs (provided by A. Kung, Columbia University) were 
grown in DMEM with 10% FBS and 1% pen/strep.
Animal Studies
These experiments were performed with approval from the Institutional Animal Care and 
Use Committee of the DFCI. Full details are given in Extended Experimental Procedures.
Synthetic RNA Spike-In and Microarray analysis
RNA samples were prepared as previously described (Loven et al., 2012). Total RNA was 
spiked-in with RNA Spike-In Mix (Ambion), treated with DNA-free™ DNase I (Ambion), 
analyzed on Agilent 2100 Bioanalyzer (Agilent Technologies) for integrity, and hybridized 
to Affymetrix GeneChip® PrimeView™ Human Gene Expression arrays (Affymetrix). Data 
analysis is described in Extended Experimental Procedures.
ChIP-seq
ChIP was carried out as previously described (Lee et al., 2006) with minor changes 
described in Extended Experimental Procedures. The following antibodies were used: 
RNAPII (Santa Cruz, sc-899), H3K4me1 (Abcam, ab8895) and H3K27ac (Abcam, ab4729).
Data Analysis
All ChIP-seq data were aligned using the short-read aligner Bowtie (version 0.12.7) 
(Langmead et al., 2009) to build version GRCh37/HG19 of the human genome. To visualize 
ChIP-seq tracks, reads were extended by 160 bases, converted into tdf files using igvtools 
(version 2.2.1) and visualized in IGV (Robinson et al., 2011). ChIP-seq peaks were detected 
using a peak-finding algorithm, MACS version 1.4.2 (Zhang et al., 2008) using the default 
p-value threshold of enrichment of 1 × 10−5 for all data sets. Active enhancers, ranked 
according to the magnitude of the H3K27ac signal, were defined as regions of ChIP-seq 
enrichment for H3K27ac and H3K4me1 outside of promoters. To identify super-enhancers 
we employed the ROSE algorithm (https://bitbucket.org/young_computation/rose) (Loven et 
al., 2013; Whyte et al., 2013) to rank the enhancers that were identified using MACS in 
which peaks within 12.5kb of one another were stitched together and these stitched 
enhancers were ranked by their difference in H3K27ac signal vs. input signal. Further details 
are given in Extended Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. THZ1 Exhibits High Potency and Selectivity Against MYCN-amplified Tumor Cells
(A) Dose-response curves of MYCN-amplified and nonamplified human NB and murine 
fibroblast cells after treatment with increasing concentrations of THZ1 for 72 hr. Percent 
cell viability relative to that of DMSO-treated cells is shown here and in (B). Data represent 
mean ± SD of 3 replicates here and in (B).
(B) Dose-response curves of NB cells treated as in (A) with the reversible CDK7 inhibitor 
THZ1R.
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(C) Cell-cycle analysis of MYCN-amplified vs. nonamplified NB cells exposed to THZ1 
(100 nM × 24 and 48 hr) by flow cytometry with propidium iodide (PI) staining. Results are 
representative of 3 replicates. The scale and axes are indicated in the lower left corner.
(D) Apoptosis analysis in MYCN-amplified and nonamplified NB cells treated with THZ1 as 
in (C) by flow cytometry with Annexin V staining. Data represent mean ± SD of 3 
replicates. ***p<0.0001, **p<0.001 (Student’s t-test).
(E) Tumor volumes of MYCN-amplified human NB xenografts in NU/NU (Crl:NU-
Foxn1nu) mice treated with THZ1 (10 mg/kg IV twice daily) (n=14) or vehicle (n=9) for 28 
days. Mean ± SD values are presented. ***p<0.001; **p<0.01; *p<0.05 (multiple t-test, 
Holm-Sidak method).
(F) Immunohistochemical (IHC) analysis of morphology (hematoxylin & eosin, H&E), 
proliferation (Ki67) and apoptosis (cleaved caspase 3, CC3) in tumors harvested from 
animals treated with vehicle or THZ1 as in (E) for 12 days. Scale bar, 25 μM.
See also Figure S1, Table S1.
Chipumuro et al. Page 16
Cell. Author manuscript; available in PMC 2015 November 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. THZ1 Inhibits General Transcription and Cell Cycle Regulation in MYCN-amplified 
Tumor Models
(A) Immunoblot analysis of RNA Pol II CTD phosphorylation in MYCN-amplified and 
nonamplified NB cells treated with DMSO or THZ1 at the indicated concentrations for the 
indicated times.
(B) Immunoblot analysis of RNA Pol II CTD phosphorylation in human NB xenograft 
tumor cells obtained from mice treated with vehicle or THZ1 (10 mg/kg IV twice daily) for 
12 days.
(C) Immunoblot analysis of MCL1 in MYCN-amplified (Kelly, NGP) vs. nonamplified (SK-
N-FI, SH-SY5Y) NB cells following treatment with THZ1 at the indicated concentrations 
and durations.
(D) Immunoblot analysis of proteins involved in cell cycle progression in MYCN-amplified 
(Kelly, IMR-32) and nonamplified (SH-SY5Y) NB cells following treatment with THZ1 
100 nM for 3 and 6 hr.
See also Figure S2
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Figure 3. THZ1 Causes Massive Downregulation of Actively Transcribed Genes in MYCN-
overexpressing NB Cells
(A) Heat map of gene expression values in MYCN-amplified and nonamplified cells treated 
with THZ1 (100 nM for 6 hr) vs. DMSO. Rows show z-scores calculated for each cell type.
(B) Quartile box plots of log2 fold changes in gene expression in MYCN-amplified and 
nonamplified cells treated with DMSO or THZ1 at the same dose and duration as in (A). 
Box plot whiskers extend to 1.5 times the interquartile range (n=18,665 expressed genes, 
p<10−15 for Kelly vs. SH-SY5Y and IMR-32 vs. SH-SY5Y, two-sided Mann-Whitney U 
test).
(C) Venn diagram depicting the overlap between sets of differentially expressed transcripts 
(THZ1 vs. DMSO) in MYCN-amplified (Kelly, IMR-32) and nonamplified (SH-SY5Y) cells 
treated with THZ1 as in (A). Red represents upregulated and blue, downregulated 
transcripts.
(D) Heat map of gene expression values of transcriptional and cell cycle CDKs in MYCN-
amplified and nonamplified cells treated with THZ1 as in (A) vs. DMSO. Rows show z-
scores calculated for each cell type.
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(E) Correlation between log2 fold changes in gene expression following THZ1 (100 nM) vs. 
DMSO treatment and actinomycin D (1 μM) vs. DMSO treatment for 6 hr. in MYCN-
amplified NB cells. R2 (coefficient of determination) calculated using a simple linear 
regression model.
See also Figure S3.
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Figure 4. Cytotoxic Effects of THZ1 are Mediated in Part Through Inhibition of MYCN 
Expression
(A) Quantitative RT-PCR (qRT-PCR) analysis of MYCN RNA expression in MYCN-
amplified Kelly cells treated with THZ1-50 nM for 0–6 hr (left) or 0–250 nM for 6 hr 
(right). Data normalized to β-actin are presented as mean ± SD of three biological replicates.
(B) Immunoblot analysis of MYCN protein expression in MYCN-amplified NB cells treated 
with the indicated doses of THZ1 for 6 or 24 hr.
(C) IHC analysis of MYCN protein expression in MYCN-amplified human NB xenograft 
models treated with either DMSO or 10 mg/kg IV twice daily of THZ1 for 12 days. Scale 
bars, 25 μM.
(D) ChIP-qPCR analysis of MYCN binding at the promoters of candidate target genes in 
MYCN-amplified cells following treatment with THZ1, 100 nM for 3 hr. Mean ± SD values 
for three replicate experiments are shown. **p<0.01 (Student’s t-test).
(E) Immunoblot analysis of the indicated proteins in MYCN-amplified NB cells expressing 
either an shRNA control (shGFP) or an shRNA directed against MYCN (shMYCN). Two 
different hairpins against MYCN [shMYCN(1) and shMYCN(3)] were used with similar 
results.
(F) qRT-PCR analysis of MYCN expression in SH-SY5Y MYCN-nonamplified cells 
engineered to express either a control vector (pLenti 6.3) or MYCN (pLenti 6.3 MYCN (left 
panel). Immunoblot analysis of MYCN protein expression in these cells (right panel).
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(G) Cell viability analysis of untransfected (SH-SY5Y), control vector-expressing (pLenti 
6.3) or MYCN-expressing (pLenti 6.3 MYCN) MYCN-nonamplified NB cells treated for 72 
hr with increasing doses of THZ1. Results are means ± SD of 3 replicates.
See also Figure S4.
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Figure 5. THZ1 Inhibits MYCN-driven Transcriptional Amplification
(A) Box plot depicting the log2 fold changes in actively transcribed genes in MYCN-
nonamplified SH-SY5Y cells transduced with MYCN (pLenti 6.3-MYCN) compared with a 
control vector (pLenti 6.3). Box plot whiskers extend to 1.5 times the interquartile range 
(n=18,665 expressed genes; p<2.2 × 10−16, two-sided Mann-Whitney U test).
(B) Heat map of all gene expression values in MYCN-nonamplified SH-SY5Y cells vs. SH-
SY5Y cells overexpressing MYCN (pLenti 6.3-MYCN) following either THZ1 (100 nM for 
6 hr) or DMSO treatment. Rows show z-scores calculated for each vector.
(C) Immunoblot analysis of MYCN, CC3 and cleaved PARP in SH-SY5Y MYCN-
nonamplified cells engineered to express either a control vector (pLenti 6.3) or MYCN 
(pLenti 6.3-MYCN) following treatment with THZ1.
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(D) Heat map of differentially expressed genes in MYCN-amplified NB cells expressing a 
MYCN shRNA vs. control shRNA. Rows show z-scores calculated for each vector.
(E) Box plots of log2 fold changes in gene expression in MYCN-amplified NB cells 
expressing a MYCN shRNA vs. a control shRNA. Box plot whiskers extend to 1.5 times the 
interquartile range (n=18,665 expressed genes; p<10−15 for shMYCN vs. shGFP, two-sided 
Mann-Whitney U test).
(F) GSEA plot depicting the correlation between the top 500 downregulated genes following 
THZ1 treatment and the rank-ordered genes that are differentially expressed after MYCN 
knockdown in MYCN-amplified NB cells.
See also Figure S5.
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Figure 6. NB Cells Possess Unique Super-enhancer Landscapes
(A) H3K27ac signal across enhancer regions for all enhancers in MYCN-amplified and 
nonamplified cells. SEs were defined as enhancers surpassing the threshold signal of 8802 in 
both cell types. In Kelly and SH-SY5Y cells, 6.2% (746/12,000) and 5.4% (1136/20,887) of 
the enhancers comprised 52% and 37%, respectively of all H3K27ac-bound enhancer signal 
and were classed as SEs.
(B) ChIP-seq profiles for H3K27ac, H3K4me1 and RNA Pol II binding at the MYCN SE 
gene locus in Kelly cells. The x axis shows genomic position and the y axis the signal of 
histone mark or Pol II binding in units of reads per million per base pair (rpm/bp). The gene 
model is depicted below and scale bars above the binding profiles.
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(C) ChIP-seq profiles for H3K27ac binding at representative SE-associated gene loci in 
MYCN-amplified and nonamplified cells. The x and y axes are as described in (B).
(D) Gene Ontology (GO) categories of SE-associated genes in MYCN-amplified (Kelly) and 
nonamplified (SH-SY5Y) cells identified using GREAT analysis (McLean et al., 2010).
(E) H3K27ac loading across enhancers in MYCN-amplified and nonamplified primary NB 
tumors. SEs were defined as having a threshold signal of ~5600 in the tumors. In NB#1 and 
NB#2, 8.5% (164/1,920) and 3.0% (109/3,561) and in NB#3, 6.4% (522/8,040) of the 
enhancers were classified as SEs.
See also Figure S6.
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Figure 7. Sensitivity of MYCN-amplified Cells to THZ1 Correlates with MYCN-associated Super-
enhancers
(A) Metagene representation of global Pol II ChIP-seq occupancy at SE- and RE-associated 
genes in cells with (Kelly) or without (SH-SY5Y) MYCN amplification treated with DMSO 
(blue) or THZ1 (red) (100 nM × 3 hr). TSS, transcription start sites.
(B) Gene tracks of RNA Pol II binding density at representative SE-associated gene loci 
after DMSO or THZ1 treatment as in (A).
(C) Left, quartile box plots of log2 fold changes in the top 300 genes associated with SEs 
and regular enhancers (RE) in MYCN-amplified cells treated with THZ1 (100 nM × 6 hr) vs. 
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DMSO. Box plot whiskers extend to 1.5 times the interquartile range (n=230 SE; n=231 RE; 
p<10−2, two-sided Mann-Whitney U test).
Right, quartile box plots of log2 fold changes in gene transcripts associated with the top-
ranked SEs unique to MYCN-amplified Kelly cells treated with THZ1 as in (A) vs. DMSO, 
compared with the expression changes of the same genes in similarly treated SH-SY5Y 
nonamplified cells. Box plot whiskers extend to 1.5 times the interquartile range (n=673; 
p<10−16, two-sided Mann-Whitney U test).
(D) Proposed mechanism for the action of THZ1 in MYCN-amplified NB. Oncogenic MYCN 
is regulated by super-enhancers leading to its high-level expression (left). Overexpressed 
MYCN invades the promoter and enhancer regions of all active genes, including itself, to 
induce global transcriptional upregulation (right). THZ1 targets the expression of both 
MYCN and MYCN-driven transcriptional amplification.
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